Market Overview

Wedbush Downgrades Sunesis Pharmaceuticals To Neutral, Shares Drop

Share:

Analysts at Wedbush downgraded Sunesis Pharmaceuticals (NASDAQ: SNSS) from Outperform to Neutral.

Sunesis Pharmaceuticals shares have jumped 57.81% over the past 52 weeks, while the S&P 500 index has surged 21.89% in the same period.

Sunesis Pharmaceuticals' shares fell 3.60% to $7.50 in pre-market trading.

Latest Ratings for SNSS

DateFirmActionFromTo
Dec 2018Initiates Coverage OnNeutral
Dec 2017UpgradesMarket PerformOutperform
Dec 2017DowngradesOutperformMarket Perform

View More Analyst Ratings for SNSS
View the Latest Analyst Ratings

Posted-In: WedbushDowngrades Analyst Ratings

 

Related Articles (SNSS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MANMaintains96.0
INTCMaintains57.0
CHNGInitiates Coverage On19.0
BRMaintains150.0
SLBMaintains41.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Stifel Nicolaus Initiates Stratasys At Buy, Shares Rise

IXYS Increases Quarterly Cash Dividend